Form 4: Inhibitor Therapeutics Director Michael Jerman Acquires and Disposes of Shares

Director Michael Jerman reports acquiring 50,000 shares of Inhibitor Therapeutics common stock as compensation and disposing of 80,411 shares.

Summary

• On April 1, 2024, Michael Allen Jerman, a director of Inhibitor Therapeutics, Inc. [INTI], acquired 50,000 shares of common stock.
• The acquisition was compensation under the company's 2014 Equity Incentive Plan.
• The price per share for the acquisition was $0.
• On April 1, 2025, Michael Allen Jerman disposed of 80,411 shares of common stock.
• Following these transactions, Jerman beneficially owns 80,411 shares of Inhibitor Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions. The disposal of shares could be seen as slightly negative, but the acquisition as compensation is a positive.

Positives

• The acquisition of shares as compensation aligns the director's interests with the company's performance.

Negatives

• The disposal of 80,411 shares by the director could be interpreted negatively by the market.

Risks

• The disposal of a significant number of shares by a director could create uncertainty among investors.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company insiders.

Stakeholder Impact

• Shareholders may react to the director's stock disposal.

Key Dates

Keywords

Inhibitor Therapeutics, INTI, Michael Jerman, Director, Stock Acquisition, Stock Disposal, Beneficial Ownership, Equity Incentive Plan, Compensation